A long-term surveillance program is anyway recommended, especially for patients with high risk-features, and the use of mTOR inhibitors should be taken into consideration in patients with residual disease after surgery and well as in those with recurrent or metastatic disease (Wagner et al., 2010, Liu et al., 2019, Italiano et al., 2010, Starbuck et al., 2016). Here, MTOR is linked to metastatic neoplasm.